News
Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...
2d
MedPage Today on MSNPrimary Surgery for Ovarian Cancer Scores a Win -- Sort OfPrespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...
3d
MedPage Today on MSNWin for Added Relacorilant in Platinum-Resistant Ovarian CancerIn addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...
Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...
ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer
Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.
Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.
Bridgerton actress Rosa Hesmondhalgh thought her bloated stomach was due to over-eating at Christmas, but a month later she ...
Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.
CBS Boston on MSN1d
A warning about an earlier outbreak of the Norovirus and a new way to detect ovarian cancerRep. Madeleine Dean's Banana Burn Against Commerce Secretary Howard Lutnick Goes Viral ...
Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.
The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results